% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • patcarr832 patcarr832 Jul 22, 2013 9:04 AM Flag

    Positive EP News in ONCS Ph II

    ONCS cannot trade in premarket, but this AM they PR'd very positive EP news in a Phase II melanoma study. Things are just going to keep getting better for both companies. Have a good day and week! A half Billion Dollar Market Cap for INO would bring over $3.00 price per share. Sounds reasonable to me!


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That is actually the information from their presentation at the Melanoma Conference in Hamburg Germany from last Thursday. This information has already impacted the SP for ONCS. I own both INO and ONCS, BTW.

      The importance of the ONCS information is that vaccination against melanoma can be an independent adjunct to other therapies that might have to be applied (therapeutic surgery, radiation and chemo) that would aid independently the long term survival of melanoma patients. There is actually an older patient who has undergone the therapy being tested and has posted on the ONCS MB. Fortunately, he has not provided any data or otherwise jeopardized the ONCS-FDA confidentiality. He just commented upon what it was like to be treated by the method. He is awaiting the 24 week evaluation. He suggested the treatment was not "painless" but he would do it again. That is a reasonable experience to divulge. Let's wish him well.


      Sentiment: Strong Buy

    • davedubosesfamily Jul 22, 2013 9:12 AM Flag

      Today - Monday, July 22, 8:58 AM OncoSec Medical's (ONCS.OB) ImmunoPulse technology for administering drugs via electroporation led to a significant change in tumor immunity in a Phase II study of patients who were given therapy called Interleukin-12 to treat metastatic melanoma. (PR) Comment! [Healthcare]

11.16+0.03(+0.27%)May 25 4:00 PMEDT